Stichting Farma ter Verantwoording

GCCP Scorecard: Hoe reageren bedrijven op de pandemie?

Farmabedrijven hebben een bijzondere verantwoordelijkheid om bij te dragen aan de realisatie van de mensenrechten en toegang tot medicijnen voor iedereen. Tools zoals deze ‘good Covid-19 company practices’ plaatsen cruciale stappen voor bedrijven in de kijker om hun verantwoordelijkheden waar te maken.

De GCCP Scorecard

  • Organisatie houdt zich aan de 'good practice'
  • Organisatie laat enige verbetering zien
  • Organisatie houdt zich niet aan de 'good practice'
  • Geen informatie beschikbaar
Covid - 19 Vaccine
CureVac
Covid - 19 Vaccine
Gamaleya Research Institute
Covid - 19 Vaccine
Novavax
Covid - 19 Vaccine
Sinopharm
Covid - 19 Vaccine
Sinovac
Covid 19 Vaccine
Pfizer
Covid 19 Vaccine
Oxford / Astra Zeneca
Covid-19 vaccine
Modernaa
Covid - 19 Vaccine
Johnson & Johnson
Casirivimab
+ imdevimab Regeneron
Bamlanivimab
Ely Lilly
Remdesivir
Gilead
A1. Publishes a global access plan for its product.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
A2. Commits to comply with human rights standards in product development & marketingClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
C1. The company commits to C-TAP or MPPClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
C2. Commits to not enforcing the exclusive rights of Covid-19 related patents.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
C3. Supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E1. The company makes the active ingredient available on reasonable grounds. [ therapeutics only]Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E2. Commits to full technology transfer to other manufacturers.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E3. Commits to non-profit or 'fair' pricing.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E4. Equitably distributes supplies globally. [vaccines only]Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E5. The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
E6. Agrees to waive exclusive rights in regulatory test data [where applicable].Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T1. Publishes its R&D costs.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T2. Publishes its profit margin.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T3. The company publishes the average and/or marginal costs of production.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T4. Publishes its production capacity.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T5. The company publishes the public subsidies it received during product development and/or testingClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T6. Publishes the text of licensing agreements.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here
T7. Registers its clinical trials in public repositories.Click hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick hereClick here

Note : Click in the middle of any colored label for additional information.

Download de GCCP Scorecard